Krazati and Erbitux Effective for KRAS G12C-Mutant Advanced mCRC
Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.
Read More
Palliative Care May Reduce Invasive Intervention Use in Early-Onset CRC
Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.
Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.
Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric/GEJ Cancer
Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.
Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
Tevimbra Plus Chemotherapy May Improve Survival in First-Line ESCC
Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.
Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset
The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.
Palliative Care May Improve Quality of Life in Esophageal Cancer
End-of-life palliative care consultations may also ease financial strain for patients with esophageal cancer.
Oral Liporaxel May Be Superior To Intravenous in Advanced Gastric Cancer
Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.
Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.
The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.
Watch
Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.
ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer
Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.
Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs
Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.
CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer
Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.
Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC
Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.
Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer
Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.
Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract
A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
Bezuclastinib Plus Sutent May Be Safe and Effective in GIST
Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.
Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis
Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.
Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers
Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.
Opdivo Plus Chemo Shows 5-Year Efficacy in Gastric, GEJ and Esophageal Cancer
Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.
SHR-1701 Combo Reduces Chemo-Related Myelosuppression in Gastric/GEJ Cancer
SHR-1701 plus chemo suppressed chemo-associated myelosuppression in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Afinitor Plus Somatuline Prolongs Survival in GEP-NETs
Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
A Commitment to New Therapies for MPN Despite Scientific Challenges
One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.
A Patient's Self-Advocacy Leads to an Essential Thrombocythemia Diagnosis in Her 30s
While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia.
Asking Questions About Treatment Options for MPN
A patient with MPN urges others to ask questions about treatment options, which may also include inquiring about clinical trials.
Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer
In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.
Empowering Patients With Cancer Through Clear Clinical Trial Communication
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.
Driven by Experience: How a Caregiver Became an MPN Advocate
An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.
